Seeking Alpha
Value, growth, long-term horizon, medium-term horizon
Profile| Send Message|
( followers)  

Interested in the high-growth prospects of the biotech industry? For a closer look at some interesting biotech names, we ran a screen.

We began by screening the biotech sector for stocks with strong liquidity, with current ratios above 3. The current ratio is current assets/current liabilities, so ratios above 3 indicate the company has at least 3 times the liquid assets to cover their short-term liabilities.

We then screened for those stocks with strong sales trends, comparing growth in revenue to growth in accounts receivable. Since accounts receivable is the portion of revenue not yet received, and there is no guarantee the money will ever be received, the smaller the portion of revenue made up of receivables the healthier the company's revenue.

We screened for stocks seeing faster growth in revenue than accounts receivable year-over-year, as well as accounts receivable comprising a smaller portion of current assets over the same time period.

(click to enlarge)

Do you think these stocks have strong sales trends? Use this list as a starting point for your own analysis.

List sorted by increase in revenue over the last year.

1. 3SBio Inc. (NASDAQ:SSRX): Engages in the research, development, manufacture, and distribution of pharmaceutical products in the People's Republic of China. Market cap at $302.36M, most recent closing price at $13.70. Current ratio at 15.54. Revenue grew by 38.24% during the most recent quarter ($139.88M vs. $101.19M y/y). Accounts receivable grew by 20.16% during the same time period ($161.19M vs. $134.15M y/y). Receivables, as a percentage of current assets, decreased from 16.91% to 16.24% during the most recent quarter (comparing 3 months ending 2011-12-31 to 3 months ending 2010-12-31).

2. Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI): Primarily focuses on oncology and hematology. Market cap at $659.48M, most recent closing price at $11.08. Current ratio at 3.18. Revenue grew by 37.29% during the most recent quarter ($59.86M vs. $43.6M y/y). Accounts receivable grew by 6.5% during the same time period ($55.38M vs. $52M y/y). Receivables, as a percentage of current assets, decreased from 37.26% to 21.07% during the most recent quarter (comparing 3 months ending 2012-03-31 to 3 months ending 2011-03-31).

3. Obagi Medical Products, Inc. (NASDAQ:OMPI): Develops and markets topical aesthetic and therapeutic prescription skin care systems. Market cap at $238.99M, most recent closing price at $12.76. Current ratio at 4.65. Revenue grew by 15.99% during the most recent quarter ($30.75M vs. $26.51M y/y). Accounts receivable grew by -0.1% during the same time period ($20.92M vs. $20.94M y/y). Receivables, as a percentage of current assets, decreased from 39.38% to 29.82% during the most recent quarter (comparing 3 months ending 2012-03-31 to 3 months ending 2011-03-31).

4. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): Develops and commercializes biopharmaceuticals for serious diseases and medical conditions. Market cap at $4.23B, most recent closing price at $36.60. Current ratio at 4.28. Revenue grew by 6.57% during the most recent quarter ($116.65M vs. $109.46M y/y). Accounts receivable grew by 1.58% during the same time period ($112.66M vs. $110.91M y/y). Receivables, as a percentage of current assets, decreased from 22.01% to 21.94% during the most recent quarter (comparing 3 months ending 2012-03-31 to 3 months ending 2011-03-31).

*Accounting data sourced from Google Finance, all other data sourced from Finviz.

Source: 4 Highly Liquid Biotech Stocks With Strong Receivable Trends